3 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 4 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Yana Najjar: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| Evaluation of Hypoxia in Primary Melanoma Pimonidazole - Melanoma | Recruiting | Yana Najjar | 50 | 2025-04-09 | 2026-06-10 | |
| RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Vusolimogene oderparepvec (RP1) - Melanoma | Early Phase 1 | Recruiting | Yana Najjar | 25 | 2024-03-07 | 2026-04-13 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
| Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma Pimonidazole - Melanoma | Recruiting | Yana Najjar | 20 | 2021-02-24 | 2026-06-11 | |
| Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Nivolumab, Axitinib - Advanced Melanoma, Unresectable Melanoma | Phase 2 | Completed | Yana Najjar | 31 | 2020-12-18 | 2025-07-15 |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Pembrolizumab Injection [Keytruda], Metformin - Advanced Melanoma | Phase 1 | Active not recruiting | Yana Najjar | 23 | 2018-02-07 | 2026-06-30 |
| Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Pembrolizumab, Vemurafenib, Cobimetinib - Melanoma | Phase 1 | Terminated | Yana Najjar | 9 | 2016-07-13 | 2022-01-03 |
| Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Pembrolizumab and high dose interferon alfa-2b (HDI) - Melanoma | Phase 1 | Completed | Yana Najjar | 31 | 2015-03-06 | 2021-02-24 |
Melanoma (8) · Immune System Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Retinitis Pigmentosa 2 (1)
Nivolumab (3) · pembrolizumab (3) · pimonidazole (2) · Axitinib (1) · HuMax-IL8 (1) · Interferon alpha-2 (1) · Introns (1) · MAPRE1 protein, human (1) · Metformin (1) · Radiosurgery (1) · Vemurafenib (1) · cobimetinib (1) · spartalizumab (1)
United States (9)
Yana M Najjar, MD (1) · Yana M. Najjar, MD (1)